You don’t go to the life sciences space looking for conventional bargains – it’s a high-growth, a high-margin sector that has attracted a lot of investor attention and the valuations reflect that. For investors who can get comfortable with the higher multiples, though, I do think there are some interesting stories, and Agilent (A) is one of them.
With research labs still operating well below normal and other end-markets like Chemicals and Energy likewise below historical norms, I see worthwhile upside for Agilent on post-pandemic normalization. I also like the company’s leverage to increased service penetration with its laboratory customer base, as well as the growth opportunities in biological drug discovery and production.
Click the link for the full article:
Agilent Leveraged To Post-Pandemic Recovery And Advanced Drug Discovery And Production
No comments:
Post a Comment